PITTSBURGH--(BUSINESS WIRE)--Pittsburgh based Lipella Pharmaceuticals Inc. today announced newly published results of a multi-site, double-blind, placebo-controlled clinical trial comparing the ...
PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative ...
Lipella Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing innovative therapies by reformulating active agents in existing generic drugs, announced that the US Food and ...
The Comirnaty 2025-2026 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, a descendant of JN.1. The Food and Drug Administration (FDA) has approved Comirnaty ® (LP.8.1-adapted monovalent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results